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Conclusion: Our results demonstrate that vaccination of camels
with MVA-S confers protects against MERS-CoV infection. In addi-
tion, induction of MVA speciﬁc antibody cross neutralize camelpox
virus, suggesting that MVA-MERS-S can be used as a dual vaccine
in dromedary camels.
http://dx.doi.org/10.1016/j.ijid.2016.02.898
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Background: Dengue is a mosquito-borne viral infection with
a very rapid global expansion during the last 50 years. This dis-
ease has become an important public health problem in Asia and
Latin America with over half the world’s population at risk1. Sanoﬁ
Pasteur is developing a recombinant, live, attenuated, tetravalent
dengue vaccine (CYD-TDV) for countries at-risk of dengue2. The
results from CYD-TDV trials are useful to observe the trends in
immunogenicity (GMT) titres across various countries.
OBJECTIVES: To assess immunogenicity titres after 3 doses of
CYD dengue vaccine in children, adolescents and adults up to 60
years by revisiting pre- and post-vaccination GMTs from Sanoﬁ
Pasteur CYD-TDV trials.
Methods&Materials: Dengue neutralizing antibody (Ab) levels
were assessed by a plaque neutralization test with a 50% endpoint
(PRNT50) for each serotype. In total, 25 clinical studies from Phase
I to Phase III have been included in the clinical development plan.
Of these 25 clinical studies, the integrated immunogenicity anal-
ysis presented here is based on results from 11 trials conducted
in 8 Asian countries (Philippines, Indonesia, Malaysia, Vietnam,
Thailand, Singapore, Australia, and India) and 6 Latin American
countries (Brazil, Colombia, Honduras, Mexico, Peru, and Puerto
Rico).
Results: Immune titres increased after 3 doses from baseline,
and higher GMTs were observed with increasing age and endemic-
ity in all countries considered at-risk of dengue. Further exploration
in older adults in Australia3 vaccinated with 3 doses of CYD-TDV,
revealed that both the 18-60 age group (N=655) and the 46-60 age
group (N=241) had similar GMTs which were higher than baseline.
Conclusion: Integrated analysis from CYD-TDV trials in chil-
dren, adolescents and adults up to 60 years of age showed a
consistent ﬁnding of higher GMTs in the vaccinated arm versus
control arm. Subjects who received 3 doses of CYD-TDV elicited
a balanced immune response against all four serotypes.
References: WHO Dengue factsheet No. 117 (updated May
2015) Guy B and al., Vaccine, 2011 Toressi et al, Vaccine, 2015
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Background: Cystic Echinococcosis (CE) is one of the most
important zoonosis parasite diseases which caused by the larval
stage of Echinococcus granulosus (Eg). The Eg14-3-3 protein is a
vaccine candidate antigen which exists in different development
stages of E. granulosus. The basement of vaccine design strate-
gies is identiﬁcation the most efﬁcacious epitopes of the antigen.
This study presents linear and conformational B cell epitopes of the
Eg14-3-3 antigen via computational tools.
Methods & Materials: The protoscoleces (PSC) of E. granulo-
sus was aspirated from infected lungs and livers of slaughtered
sheep (Tabriz, Iran) and then DNA samples were extracted. The
polymerase chain reaction (PCR) was performed using speciﬁc
primers (forward: ATGTCTTCTCTCAGTAAGCGCGA and reverse:
ATCGGCTTTCGGCGGTTCAG) and basing on the sequence in Gen-
Bank (Access No. AY942149). After sequencing the PCR products,
our regional Eg14-3-3 sequence was utilized (the sequence of our
local Eg14-3-3 shall be published soon). The linear B-cell epitopes
were predicted by Bepipred Linear Epitope Prediction algorithm
with threshold 0.35. The conformational B-cell epitopes were pre-
dicted using a sequence-based server named CBTOPE which uses
the support vector machine (SVM) threshold -0.3, and also the
three dimensional (3D) properties of the antigen such as, Rela-
tive SolventAccessibility, Number of TransmembraneDomains and
protein tertiary structure prediction. The structural details of Eg14-
3-3which are usable in the epitope-based vaccine design evaluated
via SCRATCH Protein Predictor.
Results: The Best linear B-cell epitopes were selected based
on their length (<9 amino acids) and score (highest), so that
the high scales consist of ATEVAEGDMQTT, DTLPEESYK, EQKHDG-
DAK and TGDERKQASDN. Based on CBTOPE algorithm ﬁve high
